Cargando…

Pharmacokinetics of a single dose of Aficamten (CK‐274) on cardiac contractility in a A31P MYBPC3 hypertrophic cardiomyopathy cat model

Hypertrophic cardiomyopathy (HCM) is the most prevalent cardiac disease in cats and lacks efficacious preclinical pharmacologic intervention, prompting investigation of novel therapies. Genetic mutations encoding sarcomeric proteins are implicated in the development of HCM and small molecule myosin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sharpe, Ashley N., Oldach, Maureen S., Kaplan, Joanna L., Rivas, Victor, Kovacs, Samantha L., Hwee, Darren T., Morgan, Bradley P., Malik, Fady I., Harris, Samantha P., Stern, Joshua A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Short Communications
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10099566/ https://www.ncbi.nlm.nih.gov/pubmed/36382714 http://dx.doi.org/10.1111/jvp.13103

Ejemplares similares

Effects of Aficamten on cardiac contractility in a feline translational model of hypertrophic cardiomyopathy
por: Sharpe, Ashley N., et al.
Publicado: (2023)

Hypertrophic cardiomyopathy in purpose-bred cats with the A31P mutation in cardiac myosin binding protein-C
por: Stern, Joshua A., et al.
Publicado: (2023)

Acute pharmacodynamic effects of pimobendan in client-owned cats with subclinical hypertrophic cardiomyopathy
por: Oldach, Maureen S., et al.
Publicado: (2021)

Cardiac Effects of a Single Dose of Pimobendan in Cats With Hypertrophic Cardiomyopathy; A Randomized, Placebo-Controlled, Crossover Study
por: Oldach, Maureen S., et al.
Publicado: (2019)

A genetic polymorphism in P2RY(1) impacts response to clopidogrel in cats with hypertrophic cardiomyopathy
por: Ueda, Yu, et al.
Publicado: (2021)

Platelet Activation and Clopidogrel Effects on ADP‐Induced Platelet Activation in Cats with or without the A31P Mutation in MYBPC3
por: Li, R.H.L., et al.
Publicado: (2016)

A Phase 1 Dose-Escalation Study of the Cardiac Myosin Inhibitor Aficamten in Healthy Participants
por: Malik, Fady I., et al.
Publicado: (2022)

An Update on MYBPC3 Gene Mutation in Hypertrophic Cardiomyopathy
por: Tudurachi, Bogdan-Sorin, et al.
Publicado: (2023)

MYBPC3 mutations are associated with a reduced super-relaxed state in patients with hypertrophic cardiomyopathy
por: McNamara, James W., et al.
Publicado: (2017)

Presence of known feline ALMS1 and MYBPC3 variants in a diverse cohort of cats with hypertrophic cardiomyopathy in Japan
por: Akiyama, Noriyoshi, et al.
Publicado: (2023)

Adverse events in families with hypertrophic or dilated cardiomyopathy and mutations in the MYBPC3 gene
por: Ehlermann, Philipp, et al.
Publicado: (2008)

Familial hypertrophic cardiomyopathy associated with a new mutation in gene MYBPC3
por: Aurensanz Clemente, Esther, et al.
Publicado: (2017)

Protein haploinsufficiency drivers identify MYBPC3 variants that cause hypertrophic cardiomyopathy
por: Suay-Corredera, Carmen, et al.
Publicado: (2021)

Description of a Cohort with a New Truncating MYBPC3 Variant for Hypertrophic Cardiomyopathy in Northern Spain
por: Fernández Suárez, Natalia, et al.
Publicado: (2023)

Transcriptome Analysis of Cardiac Hypertrophic Growth in MYBPC3-Null Mice Suggests Early Responders in Hypertrophic Remodeling
por: Farrell, Emily, et al.
Publicado: (2018)

Autosomal Recessive Transmission of MYBPC3 Mutation Results in Malignant Phenotype of Hypertrophic Cardiomyopathy
por: Wang, Yilu, et al.
Publicado: (2013)

The Metabolome in Finnish Carriers of the MYBPC3-Q1061X Mutation for Hypertrophic Cardiomyopathy
por: Jørgenrud, Benedicte, et al.
Publicado: (2015)

Fatal neonatal hypertrophic cardiomyopathy caused by compound heterozygous truncating MYBPC3 mutation
por: Alsters, S., et al.
Publicado: (2019)

Contractile deficits in engineered cardiac microtissues as a result of MYBPC3 deficiency and mechanical overload
por: Ma, Zhen, et al.
Publicado: (2018)

Synergistic inhibitory effects of clopidogrel and rivaroxaban on platelet function and platelet‐dependent thrombin generation in cats
por: Lo, Sara T., et al.
Publicado: (2023)

Myocardial Deformation Analysis in MYBPC3 and MYH7 Related Sarcomeric Hypertrophic Cardiomyopathy—The Graz Hypertrophic Cardiomyopathy Registry
por: Höller, Viktoria, et al.
Publicado: (2021)

Reevaluation of the South Asian MYBPC3(Δ25bp) Intronic Deletion in Hypertrophic Cardiomyopathy
por: Harper, Andrew R., et al.
Publicado: (2020)

Hypertrophic cardiomyopathy in myosin-binding protein C (MYBPC3) Icelandic founder mutation carriers
por: Adalsteinsdottir, Berglind, et al.
Publicado: (2020)

Spatial and Functional Distribution of MYBPC3 Pathogenic Variants and Clinical Outcomes in Patients With Hypertrophic Cardiomyopathy
por: Helms, Adam S., et al.
Publicado: (2020)

Identification of an elusive spliceogenic MYBPC3 variant in an otherwise genotype-negative hypertrophic cardiomyopathy pedigree
por: Torrado, Mario, et al.
Publicado: (2022)

Untargeted Metabolomics Identifies Potential Hypertrophic Cardiomyopathy Biomarkers in Carriers of MYBPC3 Founder Variants
por: Jansen, Mark, et al.
Publicado: (2023)

Contractile Defect Caused by Mutation in MYBPC3 Revealed under Conditions Optimized for Human PSC-Cardiomyocyte Function
por: Birket, Matthew J., et al.
Publicado: (2015)

Repair of Mybpc3 mRNA by 5′-trans-splicing in a Mouse Model of Hypertrophic Cardiomyopathy
por: Mearini, Giulia, et al.
Publicado: (2013)

Combined PTPN11 and MYBPC3 Gene Mutations in an Adult Patient with Noonan Syndrome and Hypertrophic Cardiomyopathy
por: Caiazza, Martina, et al.
Publicado: (2020)

A pathogenic nonsense mutation (c.1522C>T) of the MYBPC3 gene is implicated with hypertrophic cardiomyopathy
por: Ni, Erru, et al.
Publicado: (2023)

Ambulatory electrocardiography, heart rate variability, and pharmacologic stress testing in cats with subclinical hypertrophic cardiomyopathy
por: Walker, Ashley L., et al.
Publicado: (2022)

Screening Mutations of MYBPC3 in 114 Unrelated Patients with Hypertrophic Cardiomyopathy by Targeted Capture and Next-generation Sequencing
por: Liu, Xuxia, et al.
Publicado: (2015)

Multi-omics integration identifies key upstream regulators of pathomechanisms in hypertrophic cardiomyopathy due to truncating MYBPC3 mutations
por: Pei, J., et al.
Publicado: (2021)

Generation of two iPSC lines from hypertrophic cardiomyopathy patients carrying MYBPC3 and PRKAG2 variants
por: Manhas, Amit, et al.
Publicado: (2022)

A Novel Loss-of-function Mutation in MYBPC3 Causes Familial Hypertrophic Cardiomyopathy with Extreme Intrafamilial Phenotypic Heterogeneity
por: Peng, Y, et al.
Publicado: (2023)

Retrospective study of the diagnostic utility of Spec fPLin the assessment of 274 sick cats
por: Lee, Cherrie, et al.
Publicado: (2020)

Heritability and Pedigree Analyses of Hypertrophic Cardiomyopathy in Rhesus Macaques (Macaca Mulatta)
por: Ueda, Yu, et al.
Publicado: (2021)

A Small Molecule Inhibitor of Sarcomere Contractility Acutely Relieves Left Ventricular Outflow Tract Obstruction in Feline Hypertrophic Cardiomyopathy
por: Stern, Joshua A., et al.
Publicado: (2016)

Homozygous missense MYBPC3 Pro873His mutation associated with increased risk for heart failure development in hypertrophic cardiomyopathy
por: Kissopoulou, Antheia, et al.
Publicado: (2018)

CMR derived left ventricular septal convexity in carriers of the hypertrophic cardiomyopathy-causing MYBPC3-Q1061X mutation
por: Tarkiainen, Mika, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_bngfa68abd7kg41aoi47cshdp9